|
Delayed
Bombay S.E.
04:18:27 2026-11-13 EST
|
5-day change | 1st Jan Change | ||
| 2,668.20 INR | +0.49% |
|
+5.68% | +7.98% |
| Market Cap | 450B 4.78B 4.33B 3.99B 3.62B 6.82B 7.03B 47.94B 19.05B 240B 17.96B 17.58B 765B | P/E 2027 * |
38.3x | P/E 2028 * | 33.5x |
|---|---|---|---|---|---|
| Enterprise Value | 450B 4.78B 4.33B 3.99B 3.62B 6.82B 7.03B 47.94B 19.05B 240B 17.96B 17.58B 765B | EV / Sales 2027 * |
10.4x | EV / Sales 2028 * | 9.28x |
| Free-Float |
24.34% | Yield 2027 * |
1.11% | Yield 2028 * | 1.11% |
| Markets | Quality | ||
|---|---|---|---|
Bombay S.E.
| GLAXO | Delayed | |
NSE India S.E.
| GLAXO | Delayed |
Last Transcript: GlaxoSmithKline Pharmaceuticals Limited
| 1 day | +0.49% | ||
| 1 week | +5.68% | ||
| Current month | +7.43% | ||
| 1 month | +5.30% | ||
| 3 months | +0.13% | ||
| 6 months | +10.86% | ||
| Current year | +7.98% |
| 1 week | 2,510.9 |  | 2,770 |
| 1 month | 2,342.7 | | 2,770 |
| Current year | 2,088 | | 3,121.1 |
| 1 year | 2,088 | | 3,121.1 |
| 3 years | 1,472.65 | | 3,515.95 |
| 5 years | 1,228 | | 3,515.95 |
| 10 years | 1,020 | | 3,515.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
Bhushan Akshikar
CEO | Chief Executive Officer | 56 | 2022-11-30 |
Ronojit Biswas
DFI | Director of Finance/CFO | - | 2026-03-31 |
Vibhuti Gupta
COO | Chief Operating Officer | - | 2024-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Renu Sud Karnad
CHM | Chairman | 73 | 2019-03-31 |
| Director/Board Member | 59 | 2020-05-17 | |
Manu Anand
BRD | Director/Board Member | 67 | 2022-05-15 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.49% | +5.68% | +7.00% | +81.49% | 4.78B | |
| -0.70% | +4.58% | +40.23% | +138.79% | 1,271B | |
| +1.11% | +4.11% | +45.85% | +92.54% | 683B | |
| -0.18% | +2.15% | +26.25% | +112.46% | 520B | |
| -0.36% | +3.87% | +39.84% | +69.80% | 389B | |
| -0.16% | +0.01% | +60.69% | +44.94% | 362B | |
| +0.20% | +1.07% | +27.20% | +58.95% | 304B | |
| +0.38% | +0.45% | +3.69% | +36.54% | 286B | |
| -0.22% | +1.47% | +38.89% | +74.73% | 253B | |
| -1.05% | +0.23% | +36.10% | +121.22% | 208B | |
| Average | -0.05% | +2.18% | +32.58% | +83.14% | 428B | |
| Weighted average by Cap. | -0.12% | +2.68% | +37.44% | +96.81% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 43.34B 461M 417M 385M 348M 657M 677M 4.62B 1.84B 23.17B 1.73B 1.69B 73.74B | 48.47B 516M 466M 430M 390M 735M 757M 5.17B 2.05B 25.91B 1.94B 1.89B 82.48B |
| Net income | 11.85B 126M 114M 105M 95.24M 180M 185M 1.26B 502M 6.33B 473M 463M 20.16B | 13.41B 143M 129M 119M 108M 203M 209M 1.43B 568M 7.17B 535M 524M 22.81B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-13 | ₹2,668.20 | +0.49% | 4,162 |
| 26-11-12 | ₹2,655.30 | -2.61% | 4,104 |
| 26-11-11 | ₹2,726.40 | +0.57% | 9,488 |
| 26-11-09 | ₹2,710.85 | +6.77% | 35,096 |
| 26-11-08 | ₹2,538.95 | +0.56% | 2,376 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GLAXO Stock
Select your edition
All financial news and data tailored to specific country editions
